Oehler, Sebastian http://orcid.org/0000-0003-2013-7381
Lucaroni, Laura
Migliorini, Francesca
Elsayed, Abdullah
Prati, Luca http://orcid.org/0000-0002-0044-6526
Puglioli, Sara http://orcid.org/0000-0002-4795-7331
Matasci, Mattia http://orcid.org/0000-0003-4221-8852
Schira, Kristina http://orcid.org/0000-0002-6548-331X
Scheuermann, Jörg http://orcid.org/0000-0001-7746-4717
Yudin, Denis http://orcid.org/0000-0002-4103-0543
Jia, Min http://orcid.org/0009-0006-3064-9953
Ban, Nenad http://orcid.org/0000-0002-9527-210X
Bushnell, Dave http://orcid.org/0000-0001-8736-8403
Kornberg, Roger
Cazzamalli, Samuele http://orcid.org/0000-0003-0510-5664
Neri, Dario
Favalli, Nicholas http://orcid.org/0000-0002-6538-7379
Bassi, Gabriele http://orcid.org/0000-0003-0793-5223
Article History
Received: 2 September 2022
Accepted: 26 May 2023
First Online: 3 July 2023
Competing interests
: D.N. is co-founder, CEO, CSO and President of the Scientific Advisory Board of Philogen. S.O., L.L., A.E., F.M., S.P., M.M., L.P., S.C., N.F. and G.B. are employed by Philochem AG, the research and development unit of the Philogen. R.K. is member of the Board of Directors Chair and Scientific Advisory Board of NeoTX Therapeutics LTD. D.B. is CSO of the Discovery Division at NeoTX Therapeutics LTD. All other authors do not declare any conflict of interest.